Diane Gosselin

Présidente et directrice générale
Participe à 1 Session

An accomplished scientist and leader, Diane Gosselin has been very involved in the financing of innovative biomedical research for over 20 years. Since 2012, she is President and Chief Executive Officer of CQDM, she worked on the inception of CQDM when she joined the company in 2008 as Vice President, Research and Business Development. In fulfilling her mandate at CQDM, Diane Gosselin has demonstrated the relevance and value of CQDM’s model by building an impressive portfolio of 75 outstanding technologies that impact biopharmaceutical research ($89M committed), engaging a national network of over 1200 researchers from 69 research institutions (38 public and 31 private) and involving 140 mentors from CQDM’s pharmaceutical partners. She has raised $70M in funding from 13 of the largest pharmaceutical companies in the world, as well as from the Governments of Quebec and Canada. Moreover, she has been actively expanding CQDM’s reach and vision across Canada and internationally.

Before joining CQDM, Diane Gosselin worked for the Fonds de solidarité FTQ (2003-2008) where she helped several companies implement their drug development strategy. In addition, she actively contributed to a strategic initiative designed to stimulate innovation in the life sciences sector. Also, at the Fonds de solidarité FTQ, she managed an investment portfolio of approximately $40M and evaluated more than 100 investment projects in several life sciences sectors. She also worked at PROCREA BioSciences where she led the research team that developed the first worldwide non-invasive diagnostic test for endometriosis. The test was later acquired by Diagnostic Product Corporation. She also developed the world’s largest tissue bank for endometriosis research (10 hospitals, 60 gynecologists, 4500 subjects), which was also acquired by Diagnostic Product Corporation.

Diane Gosselin currently sits on the Board of Montreal lnVivo, the Canadian Institutes of Health Research (CIHR), Ontario Genomics, CATALIS Quebec and CQDM. She has also Chaired the Board of Directors of CATALIS Quebec (2017-2019) and was a Board member of the Institut national de la recherche scientifique (INRS) (2018-2019), BIOTECanada (2014-2017), CQIB (2014-2016), Cardianove and Oceanova Biotechnologies (2005-2008). Diane Gosselin was also involved in technology maturation, including in her role as a Board member of the Bio-Innovation Funds (2005-2008).

Diane Gosselin holds a Ph.D. in microbiology and immunology from Université de Montréal, as well as an Executive MBA from Université du Québec à Montréal (UQAM) and Université Paris-Dauphine. More recently, she completed a university certification program in Corporate Governance from Université Laval. Diane Gosselin is the awardee of the 2014 UQAM’s Business School Alumni “Coup de Coeur” of the jury Award for her achievements in the life sciences sector.

Sessions auxquelles Diane Gosselin participe

jeudi 21 novembre, 2019

Fuseau horaire: EST/Eastern Time (US & Canada)
9:15 AM
9:15 AM
  • L'IA au Canada : Une puissance à explorer
  • Inscription req.
  • Académie A et B
  • 9:15 AM  -  12:30 PM  | 3 heures 15 minutes
  • SymposiumVirage technologique et intelligence artificielle